InicioNTLA • NASDAQ
add
Intellia Therapeutics Inc
Cierre anterior
12,02 $
Intervalo diario
9,93 $ - 11,43 $
Intervalo anual
9,93 $ - 34,87 $
Cap. bursátil
1036,11 M USD
Volumen medio
2,36 M
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos | 9,11 M | -24,02 % |
Gastos operativos | 30,50 M | 3,73 % |
Ingresos netos | -135,71 M | -11,04 % |
Margen de beneficio neto | -1,49 mil | -46,15 % |
Beneficios por acción | -1,34 | 2,90 % |
EBITDA | -142,16 M | -10,36 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 658,11 M | -23,01 % |
Activos totales | 1173,35 M | -5,63 % |
Responsabilidades totales | 210,74 M | 2,33 % |
Patrimonio total | 962,62 M | — |
Acciones en circulación | 101,85 M | — |
Precio-valor contable | 1,27 | — |
Rentabilidad económica | -30,61 % | — |
Retorno sobre capital | -33,80 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -135,71 M | -11,04 % |
Efectivo de operaciones | -84,84 M | 16,32 % |
Efectivo de inversión | -7,71 M | -109,70 % |
Efectivo de financiación | 82,19 M | 330,28 % |
Variación neta del flujo de caja | -10,35 M | -272,58 % |
Flujo de caja libre | -35,80 M | 44,08 % |
Información sobre la empresa
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Director ejecutivo
Fundación
2014
Sitio web
Empleados
526
